VC  VenBio

http://www.venbio.com/





     Office Locations:

360 University Avenue
Palo Alto, CA 94301
Phone: +1 415-800-0800

Get all office locations for this firm with a National Database subscription or New York Database subscription.
 

Stages:

  • Early
  • Expansion
  • Growth


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    venBio is a life sciences investment firm, partnering with industry leaders to build and invest in game-changing medicines and technologies with a focus on novel therapeutics for unmet medical needs. With a presence in San Francisco, CA and New York, venBio manages both a long/ short equity strategy along with venture capital funds which are backed by leading life sciences companies and qualified financial investors. The two venBio strategic funds have invested in 14 companies to date, including: Cytos (now KURN), Aragon (acquired by J&J), Solstice, Labrys (acquired by Teva), Seragon (acquired by Roche/Genentech), Aurinia (AUPH), Heart Metabolics, Metacrine, Alexo, Precision Biosciences, Checkmate, Adheren, Apellis, and Nabriva (NBRV). In May 2016, the firm closed venBio Global Strategic Fund II, its second life sciences venture capital fund, for a total of approximately $315 million, exceeding its target of $250 million. venBio's Strategic Fund II is anchored by major investments from three strategic limited partners - Amgen, Merck, and Baxalta -along with a group of financial Limited Partners.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or New York Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Aaron Royston MD, MBA Partner
    Corey Goodman PhD Managing Partner
    David Pezeshki CFO
    Jaume Pons PhD Venture Partner
    Richard Gaster MD VP

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      06/08/2018


      Metacrine


      CA


      $65,000,000


      Series C


      01/04/2018


      Neurogastrx


      CA


      $45,000,000


      Series A


      12/07/2017


      Metacrine


      CA


      $22,000,000


      Series B


      10/09/2017


      Harmony Biosciences


      PA


      $270,000,000


      


     

    Portfolio companies include:

     

    Recent News: